Aldeyra Therapeutics (ALDX) said Thursday that it has received a complete response letter from the US Food and Drug Administration for the resubmission of its new drug application for its potential dry eye disease treatment, reproxalap.
The company said that no manufacturing or safety issues with reproxalap were identified, but the FDA's letter noted that the NDA "failed to demonstrate efficacy in adequate and well controlled studies in treating ocular symptoms associated with dry eyes."
The letter also stated that "at least one additional adequate and well controlled study to demonstrate a positive effect on the treatment of ocular symptoms of dry eye" should be conducted, the company said.
Aldyra said it plans to resubmit the NDA in the middle of the year, pending positive results from ongoing clinical trials and talks with the FDA.
Aldeyra shares were down 74% in recent premarket activity on Thursday.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。